NYKODE THERAPEUTICS ASA (NYKD.OL) Stock Price, Forecast & Analysis
Europe - OSL:NYKD - NO0010714785 - Common Stock
NYKD.OL Key Statistics, Chart & Performance
The current stock price of NYKD.OL is 2.557 NOK. In the past month the price increased by 24.36%. In the past year, price increased by 9.33%.
NYKD.OL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ARGX.BR | ARGENX SE | 68.52 | 45.35B | ||
| 1AE.DE | ARGENX SE | 67.91 | 44.95B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 21.70B | ||
| 2X1.DE | ABIVAX SA | N/A | 6.90B | ||
| ABVX.PA | ABIVAX SA | N/A | 7.12B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.81B | ||
| 5CV.DE | CUREVAC NV | 5.17 | 1.01B | ||
| NANO.PA | NANOBIOTIX | N/A | 894.88M | ||
| PHIL.MI | PHILOGEN SPA | 21.32 | 710.53M | ||
| IVA.PA | INVENTIVA SA | N/A | 502.49M | ||
| FYB.DE | FORMYCON AG | N/A | 356.93M | ||
| VLA.PA | VALNEVA SE | N/A | 324.42M |
Related stock screener links
About NYKD.OL
Company Profile
Nykode Therapeutics ASA is a clinical-stage biopharmaceutical company which engages in discovering and developing of novel immunotherapies. The company is headquartered in Oslo, Oslo and currently employs 75 full-time employees. The company went IPO on 2020-01-27. Nykode uses its vaccine technology platform to generate therapeutics in disease indications with unmet medical need. The firm develops next generation vaccines for clinical use, based on a deep understanding of immunological principles. Nykode Therapeutics’ main product candidates are VB10.16 and VB10.NEO. VB10.16 is a therapeutic cancer vaccine against HPV16-related cancers. VB10. NEO is a therapeutic cancer neoantigen vaccine. The firm also has two universal COVID-19 vaccine candidates in development.
Company Info
NYKODE THERAPEUTICS ASA
Oslo Science Park, Gaustadalleen 21
Oslo OSLO NO
Employees: 75
Phone: 4722958193
NYKODE THERAPEUTICS ASA / NYKD.OL FAQ
What does NYKODE THERAPEUTICS ASA do?
Nykode Therapeutics ASA is a clinical-stage biopharmaceutical company which engages in discovering and developing of novel immunotherapies. The company is headquartered in Oslo, Oslo and currently employs 75 full-time employees. The company went IPO on 2020-01-27. Nykode uses its vaccine technology platform to generate therapeutics in disease indications with unmet medical need. The firm develops next generation vaccines for clinical use, based on a deep understanding of immunological principles. Nykode Therapeutics’ main product candidates are VB10.16 and VB10.NEO. VB10.16 is a therapeutic cancer vaccine against HPV16-related cancers. VB10. NEO is a therapeutic cancer neoantigen vaccine. The firm also has two universal COVID-19 vaccine candidates in development.
What is the current price of NYKD stock?
The current stock price of NYKD.OL is 2.557 NOK. The price decreased by -2.55% in the last trading session.
Does NYKD stock pay dividends?
NYKODE THERAPEUTICS ASA (NYKD.OL) has a dividend yield of 39.31%. The yearly dividend amount is currently 0.
How is the ChartMill rating for NYKODE THERAPEUTICS ASA?
NYKD.OL has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the PE ratio for NYKD stock?
NYKODE THERAPEUTICS ASA (NYKD.OL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.12).
Is NYKODE THERAPEUTICS ASA (NYKD.OL) expected to grow?
The Revenue of NYKODE THERAPEUTICS ASA (NYKD.OL) is expected to decline by -100% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
NYKD.OL Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to NYKD.OL. When comparing the yearly performance of all stocks, NYKD.OL is one of the better performing stocks in the market, outperforming 87.02% of all stocks.
NYKD.OL Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to NYKD.OL. The financial health of NYKD.OL is average, but there are quite some concerns on its profitability.
NYKD.OL Financial Highlights
Over the last trailing twelve months NYKD.OL reported a non-GAAP Earnings per Share(EPS) of -0.12. The EPS increased by 90.47% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -17.27% | ||
| ROE | -18.9% | ||
| Debt/Equity | 0.02 |
NYKD.OL Forecast & Estimates
9 analysts have analysed NYKD.OL and the average price target is 5.25 NOK. This implies a price increase of 105.44% is expected in the next year compared to the current price of 2.557.
For the next year, analysts expect an EPS growth of 82.99% and a revenue growth -100% for NYKD.OL